| __timestamp | Ligand Pharmaceuticals Incorporated | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9136000 | 79838000 |
| Thursday, January 1, 2015 | 5807000 | 121816000 |
| Friday, January 1, 2016 | 5571000 | 117633000 |
| Sunday, January 1, 2017 | 5366000 | 4577000 |
| Monday, January 1, 2018 | 6337000 | 12670000 |
| Tuesday, January 1, 2019 | 11347000 | 12135000 |
| Wednesday, January 1, 2020 | 30419000 | 18942000 |
| Friday, January 1, 2021 | 62176000 | 32328000 |
| Saturday, January 1, 2022 | 52827000 | 44678000 |
| Sunday, January 1, 2023 | 35049000 | 65486000 |
Igniting the spark of knowledge
In the ever-evolving landscape of biotechnology, understanding cost dynamics is crucial. This chart offers a fascinating glimpse into the cost of revenue trends for PTC Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Over this period, PTC Therapeutics experienced a significant fluctuation, with costs peaking in 2015 at approximately 121.8 million, before stabilizing around 65.5 million in 2023. In contrast, Ligand Pharmaceuticals maintained a more consistent trajectory, with a notable spike in 2021, reaching around 62.2 million, before settling at 35 million in 2023.
These trends highlight the contrasting strategies and market responses of these two companies. While PTC Therapeutics shows a more volatile pattern, Ligand Pharmaceuticals demonstrates a steadier approach. This analysis provides valuable insights for investors and industry analysts seeking to understand the financial health and strategic direction of these biotech firms.
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs Ligand Pharmaceuticals Incorporated
GSK plc vs PTC Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs PTC Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs PTC Therapeutics, Inc.
Grifols, S.A. vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: ADMA Biologics, Inc. vs PTC Therapeutics, Inc.
Cost of Revenue Comparison: PTC Therapeutics, Inc. vs MorphoSys AG
Cost of Revenue Trends: PTC Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Viridian Therapeutics, Inc.
Cost of Revenue Trends: Ligand Pharmaceuticals Incorporated vs Mesoblast Limited
Comparing Cost of Revenue Efficiency: Ligand Pharmaceuticals Incorporated vs Taro Pharmaceutical Industries Ltd.